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In renal collecting ducts, a vasopressin-induced cAMP
increase results in the phosphorylation of aquaporin-2
(AQP2) water channels at Ser-256 and its redistribution
from intracellular vesicles to the apical membrane. Hor-
mones that activate protein kinase C (PKC) proteins
counteract this process. To determine the role of the
putative kinase sites in the trafficking and hormonal
regulation of human AQP2, three putative casein kinase
II (Ser-148, Ser-229, Thr-244), one PKC (Ser-231), and
one protein kinase A (Ser-256) site were altered to mimic
a constitutively non-phosphorylated/phosphorylated
state and were expressed in Madin-Darby canine kidney
cells. Except for Ser-256 mutants, seven correctly folded
AQP2 kinase mutants trafficked as wild-type AQP2 to
the apical membrane via forskolin-sensitive intracellu-
lar vesicles. With or without forskolin, AQP2-Ser-256A
was localized in intracellular vesicles, whereas AQP2-
S256D was localized in the apical membrane. Phorbol
12-myristate 13-acetate-induced PKC activation follow-
ing forskolin treatment resulted in vesicular distribu-
tion of all AQP2 kinase mutants, while all were still
phosphorylated at Ser-256. Our data indicate that in
collecting duct cells, AQP2 trafficking to vasopressin-
sensitive vesicles is phosphorylation-independent, that
phosphorylation of Ser-256 is necessary and sufficient
for expression of AQP2 in the apical membrane, and that
PMA-induced PKC-mediated endocytosis of AQP2 is in-
dependent of the AQP2 phosphorylation state.
In humans, the kidney is the prime organ for regulation of
body fluid osmolarity, which is maintained within strict bound-
aries. To fine-tune this balance, principal cells of the renal
collecting duct reabsorb water from pro-urine, which is under
control of the anti-diuretic hormone arginine vasopressin
(AVP).1 Upon hypovolemia or hypernatremia, pituitary-de-
rived AVP binds its V2 receptor in the basolateral membrane of
these cells and initiates an intracellular cAMP signaling cas-
cade that causes a transient increase in cytosolic calcium (1)
and the activation of protein kinase A (PKA), which in turn
phosphorylates homotetrameric aquaporin-2 (AQP2) water
channels and possibly other proteins. Consequently, AQP2-
containing vesicles fuse with the apical membrane, rendering
the principal cells water-permeable (2, 3). Driven by an osmotic
gradient, water will then enter these cells via AQP2 and will
exit the cells via AQP3 and AQP4, located in the basolateral
membrane, a process in which urine is concentrated.
By using antibodies that recognize Ser-256-phosphorylated
AQP2 (p-AQP2), Nishimoto et al. (4) were able to show that in
vivo AVP-induced redistribution of AQP2 from vesicles to the
apical membrane coincides with phosphorylation of Ser-256. By
using similar antibodies, Christensen et al. (5) demonstrated
that p-AQP2 is, besides the apical membrane, also present in
intracellular vesicles of principal cells and that the intracellu-
lar distribution of AQP2 is regulated via V2 receptors by alter-
ing the phosphorylation state of Ser-256 in AQP2. In a later
study, water permeability analyses of Xenopus oocytes express-
ing different ratios of AQP2-S256A and AQP2-S256D (which
mimic non-phosphorylated and phosphorylated AQP2, respec-
tively) indicated that three or more monomers in an AQP2
tetramer need to be phosphorylated at Ser-256 for a steady
state plasma membrane localization of AQP2 (6), which pro-
vided an explanation for the detection of p-AQP2 in intracellu-
lar vesicles. The retention of AQP2-S256A in intracellular ves-
icles of LLC-PK1 cells upon treatment with forskolin, while
wt-AQP2 in such cells migrated to the basolateral membrane,
revealed that phosphorylation of Ser-256 in AQP2 is essential
for re-distribution to the basolateral membrane (7, 8). At pres-
ent, however, it is unclear whether phosphorylation of Ser-256
is essential and/or sufficient for AQP2 translocation to the
apical membrane.
Retrieval of AQP2 from the apical membrane of principal
cells, which results in a reduction in water reabsorption and
urine concentrating ability, is mediated by removal of AVP and
by several hormones that activate the protein kinase C (PKC)
pathway. Some of these hormones (ATP/UTP, endothelin) are
thought to activate PKCs that block the AVP-triggered in-
crease in cAMP (9, 10). In contrast, other hormones, such as
epidermal growth factor, prostaglandin E2, and agonists of
muscarinic receptors did not interfere with the AVP-mediated
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cAMP increase and, therefore, were suggested to act on the
AQP2 shuttling process only (11–13). Because the inhibitory
effect of these latter hormones was absent upon co-treatment
with PKC inhibitors (10, 12) and phorbol 12-myristate 13-
acetate (PMA), which is a specific activator of several PKCs
(14), also inhibits AVP-induced water permeability (13), these
hormones were suggested to activate PKC isotypes that inter-
fere with shuttling of AQP2 to the apical membrane. For some
proteins, it has been shown that PKCs exert their effect
through activation of casein kinase II (CKII) proteins (15, 16).
At present, however, it is unknown whether the AVP-counter-
acting PKCs mediate the re-distribution of AQP2 to intracel-
lular vesicles via direct or indirect (e.g. through CKII)
(de-)phosphorylation of AQP2 or whether it occurs independent
of the AQP2 phosphorylation state.
Besides modulating the steady state localization of a protein
in response to hormonal stimulation, the transit of proteins
from the endoplasmic reticulum (ER) to their final subcellular
location can also be a phosphorylation-dependent process. For
example, phosphorylation of the N-methyl-D-aspartate receptor
NR1 and caveolin-1 enables these proteins to exit the ER (17,
18), whereas translocation of numerous proteins from the
trans-Golgi network to intracellular compartments or the
plasma membrane and vice versa is also regulated by phospho-
rylation events (19–20). Since such phosphorylation events can
be transient, lasting only minutes (21, 22), the importance of a
phosphorylation event can be easily missed, which will not
occur when such a site is constitutively phosphorylated or
non-phosphorylated. Several studies have shown that the neg-
ative charge introduced by phosphorylation can often be mim-
icked by changing a phosphorylation site Ser/Thr residue for a
Glu or Asp (23, 24), whereas phosphorylation of such a site can
be prevented by changing it to an Ala residue (25, 26).
Human AQP2 contains three phosphorylation consensus se-
quences for CKII (Ser-148, Ser-229, and Thr-244), one for PKC
(Ser-231), and one for PKA (Ser-256), and in Madin-Darby
canine kidney (MDCK) cells, the routing to intracellular stor-
age vesicles and the AVP-regulated shuttling of heterologously
expressed human AQP2 to and from the apical membrane is
similar to those processes in principal renal cells (27). There-
fore, to address the role of the putative phosphorylation sites in
human AQP2 in these processes, MDCK cell lines that stably
expressed AQP2 proteins, in which each putative kinase site
was changed into an Ala or Glu/Asp residue, were generated
and analyzed in detail.
EXPERIMENTAL PROCEDURES
Expression Constructs—For expression of AQP2-S256A and AQP2-
S256D in MDCK cells, the encoding cDNA fragments were cut from
pT7Ts-AQP2-S256A and pT7Ts-AQP2-S256D constructs (6, 28) with
BglII and SpeI and cloned into the BglII and XbaI sites of the mam-
malian expression vector pCB6 (29).
To generate pCB6 constructs for expression of the other kinase site
mutants, three point PCRs were performed. For this, sense primers for
AQP2-S148A (5-CATCTTCGCCGCCACCGATGA-3), S148D (5-GCA-
TCTTCGCCGACACCGATGAGC-3), S229A (5-CCAGCCAAGGCCCT-
GTCGGA-3), S229D (5-CCGCCAGCCAAGGATCTGTCGGAG-3),
S231A (5-AAGAGCCTGGCGGAGCGCCT-3), S231D (5-CAAGAGCC-
TGGATGAGCGCCTGG-3), T244A (5-GAGCCGGACGCCGATTGGG-
A-3), and T244E (5-GGAGCCGGACGAGGATTGGGAGG-3) or their
corresponding antisense primers were used in combination with a
pT7Ts reverse primer (5-GCTTAGAGACTCCATTCGGG-3) or T7
primer, respectively, in a standard PCR with pT7Ts-AQP2 (28) as a
template. The resulting fragments were isolated, and a second PCR,
using both fragments as template, combined with the pT7Ts reverse
and T7 primer was performed to generate the full-length mutated AQP2
fragment. Subsequently, these fragments were digested with BglII and
SpeI and ligated into the BglII and XbaI sites of pCB6. Introduction of
only the desired mutations was confirmed using DNA sequence
analysis.
Cell Culturing and Transfection of MDCK Cells—MDCK type I cells
(27) were grown in Dulbecco’s modified Eagle’s medium (DMEM) sup-
plemented with 5% (v/v) fetal calf serum at 37 °C in 5% CO2. For
transfection of MDCK cells, 25 g of purified circular DNA was trans-
fected using the calcium-phosphate precipitation technique as de-
scribed in detail previously (30, 31). Twenty four hours after transfec-
tion the cells were trypsinized, divided over 6 Petri dishes, and
expanded in medium containing 800 g/ml G418 (Invitrogen). Ten to
fourteen days after transfection, individual clones were selected and
grown on selection drug for 4 weeks.
Immunoblotting—Protein samples were denatured by incubation for
30 min at 37 °C in 1 Laemmli buffer, subjected to electrophoresis on
a 13% SDS-polyacrylamide gel (Fluka Biochimica, Switzerland), and
blotted onto polyvinylidene fluoride membranes (Millipore Corp., Bed-
ford, MA) as described previously (32). Membranes were blocked for 1 h
in 5% nonfat dried milk in TBS-T (20 mM Tris-HCl, 73 mM NaCl, 0.2%
Tween 20, pH 7.6) and subsequently incubated with 1:3000 diluted
affinity-purified rabbit AQP2 antibodies (raised against the 15 COOH-
terminal amino acids of rat AQP2 (33)) or rabbit antibodies directed
against Ser-256-phosphorylated AQP2 (AN83-2) ((4), diluted in TBS-T
with 1% nonfat dried milk. As secondary antibodies, goat anti-rabbit
antibodies coupled to horseradish peroxidase (1:5000 in TBS-T, Sigma)
were used. Proteins were visualized using enhanced chemilumines-
cence (Pierce).
Immunocytochemistry—Cells seeded at 1.5  105 cells/cm2 were
grown on 1.13-cm2 polycarbonate filters (Corning Costar Europe, Bad-
hoevedorp, The Netherlands) for 2 days. After subsequent overnight
treatment with 5  105 M indomethacin, cells were incubated for 45
min with DMEM with or without 5  105 M forskolin. To activate
PKCs following forskolin treatment, filters were subsequently incu-
bated in DMEM with forskolin and 107 M PMA (Sigma) for 45 min. In
these cases, cells incubated for 90 min with indomethacin with or
without forskolin were taken as controls. After these incubations cells
were washed twice with PBS-CM (PBS with 0.1 mM CaCl2, 1 mM MgCl2)
and fixed in 3% paraformaldehyde for 30 min. Following quenching of
aldehyde groups with 50 mM NH4Cl in PBS for 15 min, cells were
permeabilized with 0.2% SDS in PBS for 5 min, incubated with goat
serum dilution buffer (GSDB; 16% goat serum, 0.3% Triton X-100, 0.3 M
NaCl in PBS) for 30 min to block nonspecific antibody binding, and
incubated overnight with a mixture of a 1:100 dilution of affinity-
purified rabbit anti-AQP2 antibody (33) in GSDB. After washing twice
with permeabilization buffer (0.3% Triton X-100, 0.1% BSA in PBS),
filters were incubated with 1:100 diluted goat anti-rabbit antibodies
coupled to Alexa 594 (Molecular Probes, Eugene, OR) in GSDB for 45
min. Next, filters were rinsed twice with permeabilization buffer and
mounted on glass slides with Vectashield (Vector Labs, Burlingame,
CA). Images were obtained with a Bio-Rad confocal laser scanning
microscope (CLSM) using a 60 oil-immersion objective.
Side-specific Biotinylation—MDCK cells were seeded at 1.5  105
cells/cm2 on 9.6-cm2 polycarbonate filters (Corning Costar Europe, Bad-
hoevedorp, The Netherlands), grown, and treated as described above.
Next, the cells were washed twice with ice-cold PBS-CM and incubated
twice for 20 min at 4 °C with 500 l of 1.5 mg/ml Sulfo-NHS-SS-Biotin
(Pierce) in biotinylation buffer (10 mM triethanolamine, 2 mM CaCl2,
and 125 mM NaCl, pH 8.9) applied to the apical surface of the cells.
Subsequently, the filters were incubated for 5 min with quenching
solution (50 mM NH4Cl in PBS-CM) at 4 °C and rinsed twice with cold
PBS-CM. After the filters were cut from their plastic support, 1 ml of
lysis buffer (150 mM NaCl, 20 mM Tris-HCl, pH 8.0, 5 mM EDTA, 1%
Triton X-100, 0.2% BSA, 1 mM phenylmethylsulfonyl fluoride, 5 g/ml
leupeptin, and 5 g/ml pepstatin) was added and incubated for 30 min
at 37 °C. Subsequently, the cells were scraped and transferred to
Eppendorf tubes. After centrifugation for 5 min, the supernatant was
added to streptavidin beads (30 l/sample), which had been pre-washed
twice with high salt buffer (500 mM NaCl, 5 mM EDTA, 50 mM Tris-HCl,
pH 7.5, 0.1% Triton X-100) and twice with lysis buffer. After incubation
for 16 h at 4 °C, the beads were centrifuged for 5 min and washed twice
with high salt buffer, twice with lysis buffer, and once with 10 mM
Tris-HCl, pH 7.5. Finally, the beads were sucked dry with a 30-gauge
needle, resuspended in 30 l of 1 Laemmli buffer, and denatured for
30 min at 37 °C.
Orthophosphate Labeling—Transfected MDCK cells were seeded as
described for side-specific biotinylation. Two days after seeding, cells
were treated overnight with medium containing indomethacin (Sigma).
Next, filters were cut from their support and washed once with serum/
phosphate-free DMEM (ICN Biomedicals, The Netherlands, Europe).
Subsequently, the medium was replaced by serum/phosphate-free
DMEM (1 ml/filter) containing indomethacin and 20 Ci/ml
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[32P]orthophosphate (Amersham Biosciences). After 3 h of incubation at
37 °C the medium was replaced by medium containing indomethacin
with or without forskolin and 20 Ci/ml [32P]orthophosphate for 1 h.
Subsequently, for PKC induction, cells treated with forskolin were
incubated with medium containing indomethacin, forskolin, PMA, and
20 Ci/ml [32P]orthophosphate for an additional hour. Next, the cells
were washed twice with ice-cold wash buffer (PBS  2 mM EDTA)
containing 10 mM NaF and 0.5 mM Na3VO4 to inhibit dephosphoryl-
ation. Subsequently, cells were scraped and homogenized in 750 l of
ice-cold lysis buffer (100 mM Tris-HCl, 150 mM NaCl, 2 mM EDTA, 0.5%
sodium deoxycholate, 0.1% SDS, 0.5% Nonidet P40) containing 10 mM
NaF and 0.5 mM Na3VO4. The lysates were transferred to Eppendorf
tubes and centrifuged for 10 min at 4 °C. The cleared lysate was sub-
jected to immunoprecipitation.
Immunoprecipitation—10 l of protein A-agarose beads (Kem-En-
Tec A/S, Copenhagen, Denmark) per sample were washed twice in lysis
buffer 1% BSA. Per sample, 4 l of rabbit 7 anti-AQP2 antibodies was
added to 400 l of lysis buffer and rotated overnight at 4 °C. Before use,
the antibody-coupled protein A beads were washed twice in ice-cold
lysis buffer. The washed antibody-bound beads were incubated with
cleared lysate for 16 h, washed four times with lysis buffer containing
phosphatase inhibitors, sucked dry with a 30-gauge needle, and resus-
pended in 30 l of 1 Laemmli buffer. [32P]Orthophosphate-labeled
samples were split into two equal portions of which one was immuno-
blotted for AQP2, and the second was subjected to SDS-PAGE. The gels
were dried and exposed to film for3 days using two amplifying screens
at 80 °C. Relative quantification of the signals was performed with a
PhosphorImager.
RESULTS
Trafficking of AQP2 to Intracellular Vesicles Is Phosphoryl-
ation-independent—To determine the role of phosphorylation
of Ser-148, Ser-229, Ser-231, Thr-244, and Ser-256 in the tar-
geting and regulation of shuttling of AQP2, all these sites were
independently mutated into alanines to mimic a non-phospho-
rylated state or into glutamic (Thr-244) or aspartic acids
(others) to mimic a phosphorylated state (Fig. 1). Eucaryotic
expression constructs coding for these proteins were stably
transfected into MDCK cells. Immunoblot analysis of the se-
lected clones revealed that, except for AQP2-S148D, all AQP2
mutants were mainly expressed as unglycosylated 29-kDa pro-
teins, which is also the most prominent band for wt-AQP2 in
MDCK cells (Fig. 4). AQP2-S148D, however, was mainly ex-
pressed as 29- and 32-kDa AQP2 proteins (Fig. 2), which has
been shown to be indicative for AQP2 proteins retained in the
ER (34). Therefore, this mutant was left out of further
analyses.
To determine the effects of the introduced mutations on the
targeting of AQP2 from the organelle of synthesis (ER) to
intracellular vesicles, the cell lines were treated with indo-
methacin to lower endogenous cAMP levels and subjected to
immunocytochemistry. With the exception of AQP2-S148D and
AQP2-S256D, CLSM analysis revealed a vesicular localization
for all AQP2 mutants that was similar to that of wt-AQP2 (Fig.
3, left column). AQP2-S148D revealed a dispersed intracellular
staining, which did not change with forskolin or forskolin/PMA
treatments and is typical for ER-retained proteins. Strikingly,
AQP2-S256D was, in contrast to wt-AQP2 and all other AQP2
mutants, expressed in the apical membrane.
Phosphorylation of Ser-256 Is Necessary for Expression of
AQP2 in the Apical Membrane—To determine whether the
introduced kinase site mutations affected the cAMP-induced
re-distribution of AQP2 from intracellular vesicles to the apical
membrane, all cell lines were treated with forskolin and sub-
jected to immunocytochemistry. CLSM analysis revealed that
all AQP2 mutants were mainly expressed in the apical plasma
membrane as has been found previously for wt-AQP2, except
for AQP2-S256A (Fig. 3, middle column). Of this latter mutant,
the vesicular localization did not change upon forskolin treat-
ment, which indicated that phosphorylation of Ser-256 is es-
FIG. 2. Immunoblot analysis of AQP2-S148D. Lysates of repre-
sentative cell lines expressing wt-AQP2 or AQP2-S148D were immuno-
blotted for AQP2. For wt-AQP2, the unglycosylated 29-kDa and com-
plex-glycosylated 40–45-kDa bands were obtained. Besides the 29-kDa
band, a 32-kDa high mannose band is detected for AQP2-S148D, which
indicates that this mutant is retained in the ER.
FIG. 1. Putative phosphorylation
sites in AQP2. AQP2 consist of six trans-
membrane domains and has its NH2 and
COOH termini intracellularly. The puta-
tive phosphorylation sites and the Ala or
Glu/Asp residues in which they were
changed to mimic constitutively non-
phosphorylated or phosphorylated AQP2
forms, respectively, are indicated by
arrows.
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sential for re-distribution of AQP2 from vesicles to the apical
membrane.
PMA-induced Endocytosis of AQP2 from the Apical Plasma
Membrane Is Independent of the Phosphorylation State of
AQP2—In several in vivo studies, it has been shown that
hormones and PMA that activate the PKC pathway, counteract
the AVP-induced re-distribution of AQP2 from vesicles to the
apical membrane in collecting duct cells and, therefore, the
concentration of urine (13, 35). To test whether this process
could be simulated in MDCK cells and whether the kinase site
mutants act differently upon activation of the PKC pathway,
all cell lines were pre-treated with forskolin and subsequently
treated with forskolin and PMA followed by immunocytochem-
istry. CLSM analysis revealed that wt-AQP2 as well as all
kinase site mutants were re-distributed from the apical mem-
brane to intracellular vesicles (Fig. 3, right column). The vesic-
ular localization of AQP2-S256A was not changed by the com-
bined forskolin-PMA treatment. These results indicated that
neither phosphorylation of the PKC consensus site nor modifi-
cation of any other putative kinase site was needed for PMA-
induced translocation of AQP2 from the apical membrane to
intracellular vesicles. Because AQP2-S256D is also internal-
ized with PMA, these data also suggested that the PKC-
induced redistribution of AQP2 to intracellular vesicles is an
event that is independent of de-phosphorylation of the PKA
phosphorylation site.
To biochemically establish expression of the AQP2 proteins
in the apical membrane, all cell lines were treated as above and
subjected to an apical cell surface biotinylation assay. Immu-
noblotting revealed that forskolin treatment strongly increased
the apical membrane expression of all AQP2 proteins (only
shown for wt-AQP2, AQP2-S229A/S229D, and AQP2-S231A/
S231D), except for AQP2-S256A and AQP2-S256D (Fig. 4).
AQP2-S256A was not detected in the apical membrane,
whereas the apical membrane expression of AQP2-S256D in
unstimulated cells was not further increased with forskolin.
Incubation with forskolin-PMA following forskolin treatment
again decreased the apical membrane expression of all kinase
site mutants to undetectable levels. Immunoblotting of equiv-
alents of the biotinylated and lysed cells revealed that all cell
lines expressed well detectable levels of wt-AQP2 or of the
AQP2 mutants (Fig. 4, Total).
Forskolin Specifically Enhances Phosphorylation of Ser-
256—To determine whether the forskolin and forskolin-
PMA-induced redistribution of AQP2 coincided with a changed
phosphorylation of the AQP2 protein, wt10 cells and AQP2-
S256A-expressing cells were not stimulated or treated with
forskolin or forskolin-PMA in the presence of radioactive
orthophosphate. After this treatment, AQP2 proteins were im-
FIG. 4. Apical cell surface expression of the kinase site mu-
tants of AQP2. Cells expressing wt-AQP2 or the AQP2 kinase site
mutants (indicated) were grown and treated with indomethacin (I),
indomethacin/forskolin (IF), or indomethacin/forskolin/PMA (IFP) as
described in the legend of Fig. 3 and subjected to a cell surface biotiny-
lation assay. Biotinylated proteins were precipitated with streptavidin-
agarose beads and immunoblotted for AQP2. A sample of the lysed cells
was immunoblotted in parallel to visualize the amount of mutant
proteins expressed. The data confirmed the results obtained by
immunocytochemistry.
FIG. 3. Immunocytochemical analy-
sis of MDCK cells expressing the dif-
ferent phosphorylation site mutants.
X-Z confocal images of MDCK cells ex-
pressing wt-AQP2 or the different phos-
phorylation site mutants are indicated.
These cells were grown to confluence and
incubated overnight with indomethacin
(I) to reduce basal cAMP levels. Cells
were then incubated with forskolin (IF)
for 45 min or with forskolin for 45 min
followed by PMA and forskolin for 45 min
(IFP), both in the presence of indometha-
cin. After fixation, the cells were sub-
jected to immunocytochemistry using an-
ti-AQP2 antibodies. AQP2-S148D shows a
dispersed ER-like pattern. All mutants,
except AQP2-S256A/S256D, were sorted
and redistributed as observed for wt-
AQP2. With or without forskolin, AQP2-
S256A was retained in vesicles, whereas
AQP2-S256D was localized in the apical
membrane. Upon the combined forskolin/
PMA treatment, all AQP2 proteins were
internalized, except AQP2-S256A.
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munoprecipitated from lysed cells, split into two equal por-
tions, and immunoblotted for AQP2 or loaded on a gel and
exposed to film. Immunoblotting revealed that per cell line
equal amounts of AQP2 were loaded for each condition tested
(Fig. 5, lower panel). Determination of the level of phosphoryl-
ation of wt-AQP2 in wt10 cells revealed that wt-AQP2 was
already phosphorylated without stimulation, which was,
following normalization for the amounts of AQP2 loaded,
increased 2-fold upon stimulation with forskolin.
In contrast to wt-AQP2, AQP2-S256A was not labeled in
unstimulated, forskolin-stimulated or forskolin-PMA-treated
cells, whereas the AQP2-S256A expression was higher than
wt-AQP2 (Fig. 5). These results showed that under steady state
conditions only Ser-256 in AQP2 is detected as being phospho-
rylated and that its level of phosphorylation is increased with
forskolin.
PMA-induced Endocytosis of AQP2 Is Independent of Ser-256
De-phosphorylation—Data obtained for AQP2-S256A and
AQP2-S256D described above demonstrated the importance of
phosphorylation of Ser-256 to re-distribute AQP2 from intra-
cellular vesicles to the apical membrane. We also wanted to
determine whether forskolin-induced translocation to the
plasma membrane and subsequent re-location to intracellular
vesicles with forskolin-PMA treatment coincides with an in-
creased, respectively decreased, phosphorylation of AQP2 at
Ser-256. Therefore, the different cell lines were treated as
described above and lysed. Immunoblotting of the obtained
samples, using antibodies specifically recognizing Ser-256-
phosphorylated AQP2 (4), revealed that forskolin strongly in-
creased the level of Ser-256 phosphorylation of all AQP2 kinase
site mutants that were re-distributed from vesicles to the api-
cal membrane (Fig. 6; shown for wt-AQP2, AQP2-S229A/S229D
and AQP2-S231A/S231D), with the exception of AQP2-S256A/
S256D. Neither AQP2-S256A nor AQP2-S256D could be de-
tected with these antibodies, presumably because these muta-
tions disrupt the epitope recognized by the antibody (not
shown).
Surprisingly, treatment with forskolin-PMA following fors-
kolin treatment did not appear to reduce the level of phospho-
rylation of Ser-256 (Fig. 6). These results demonstrated that
the PMA-induced re-distribution of AQP2 from the apical mem-
brane to intracellular vesicles occurred independent of de-phos-
phorylation of Ser-256.
DISCUSSION
AQP2 Routing to cAMP-sensitive Storage Vesicles Is a Phos-
phorylation-independent Process—In this study, putative ki-
nase sites were changed into Ala or Glu/Asp residues to inves-
tigate the involvement of putative phosphorylation sites in
AQP2 routing and regulation of its shuttling in MDCK cells.
Immunocytochemical analysis revealed that, except for
AQP2-S148D, all AQP2 kinase site mutants were routed to
intracellular vesicles, as shown by the observed spot-like struc-
tures. The dispersed staining of AQP2-S148D (Fig. 3) is typical
for an ER-retained protein. This was confirmed by the appear-
ance of a 32-kDa band on immunoblot (Fig. 2), which has been
shown to represent a high mannose glycosylated form of AQP2
(32). One could argue that the ER retention of AQP2-S148D
indicates that AQP2 is phosphorylated at Ser-148 while resid-
ing in the ER and needs to be de-phosphorylated to continue its
route to storage vesicles. Inconsistent with this, however, is
that AQP2-S148A, which cannot be phosphorylated at Ser-148,
is not impaired in its routing to intracellular vesicles (Fig. 3).
Also Ser-148 is located close to or is part of transmembrane
domain four (Fig. 1), and transmembrane domains are consid-
ered to be highly sensitive to amino acid changes, resulting in
improperly folded proteins. Indeed, many of the misfolded
AQP2 proteins, encoded in patients suffering from nephrogenic
diabetes insipidus, are caused by mutations in transmembrane
domains (36). Most likely, therefore, AQP2-S148D is a mis-
folded protein. Because all other AQP2 kinase site mutants,
except AQP2-S256A (see below), are, as wt-AQP2, translocated
from vesicles to the apical membrane upon forskolin treatment
(Figs. 3 and 4), our data indicate that the routing of AQP2
to cAMP-sensitive storage vesicles is (de-)phosphorylation-
independent.
Phosphorylation of Ser-256 Is Necessary and Sufficient for
Localization of AQP2 in the Apical Plasma Membrane—By
using LLC-PK1 cells expressing AQP2-S256A, it has been
shown that phosphorylation of Ser-256 is needed for AQP2
translocation from vesicles to the basolateral membrane (7, 8).
The vesicular localization of AQP2-S256A in oocytes indicated
that also in these cells phosphorylation of Ser-256 was essen-
tial for plasma membrane expression (6). In contrast, the
exclusive plasma membrane expression of AQP2-S256D in
oocytes indicated that this protein mimics constitutively phos-
phorylated AQP2, because this localization is identical to that
of wt-AQP2, which is in these cells under basal conditions
phosphorylated at Ser-256 to a high level (6). Because the level
FIG. 5. Phosphorylation of wt-AQP2 and AQP2-S256A in MDCK
cells. Cells expressing wt-AQP2 or AQP2-S256A were grown and
treated with indomethacin (I), indomethacin/forskolin (IF), or indo-
methacin/forskolin/PMA (IFP) as described in the legend of Fig. 3 and
subjected to [32P]orthophosphate labeling. After lysis, the AQP2 pro-
teins were immunoprecipitated, split in two portions of which one was
separated on SDS-PAGE and autoradiographed (upper panel). The sec-
ond portion was immunoblotted for AQP2 (lower panel). Unglycosylated
(AQP2) and complex-glycosylated AQP2 (cg-AQP2) are indicated, and
the mass of marker proteins in kDa is given on the left. Wt-AQP2 shows
a clear increase in phosphorylation with forskolin, whereas AQP2-
S256A is not labeled under any condition.
FIG. 6. Phosphorylation of wt-AQP2 and the kinase site mu-
tants at Ser-256. Cells expressing wt-AQP2 or the AQP2 kinase site
mutants (only Ser-229 and Ser-231 mutants are shown) were grown
and treated with indomethacin (I), indomethacin/forskolin (IF), or in-
domethacin/forskolin/PMA (IFP) as described in the legend of Fig. 3 and
immunoblotted using an antibody specifically recognizing PKA-phos-
phorylated AQP2 (p-AQP2) or recognizing all AQP2 forms (total AQP2).
Equal amounts of AQP2 proteins were loaded (right panel). With all
AQP2 kinase site mutants, phosphorylation at Ser-256 was increased
with forskolin, which did not decrease upon subsequent incubation with
forskolin and PMA.
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of Ser-256 phosphorylation could not be modulated in oocytes,
its role in the regulation of AQP2 shuttling could not be studied
further in these cells.
In MDCK cells, however, induction of the cAMP pathway by
AVP, cAMP, or forskolin is needed to induce the re-distribution
of wt-AQP2 from storage vesicles to the apical membrane (37),
which coincides with an increased level of Ser-256 phosphoryl-
ation (Figs. 5 and 6). In these cells, forskolin treatment did not
change the vesicular localization of AQP2-S256A (Fig. 3),
which was underscored by the lack of detection of AQP-S256A
in the apical membrane with the biotinylation assay (Fig. 4).
This clearly showed that phosphorylation of Ser-256 in wt-
AQP2 is also needed for AQP2 translocation to the apical
plasma membrane. Recently, it was speculated that Ser-256
needs to be phosphorylated by the Golgi CKII and subsequently
de-phosphorylated before its itinerary to storage vesicles could
be continued (38). Co-localization studies using antibodies that
recognize the Golgi marker proteins 58K and giantin, however,
did not reveal any co-localization with AQP2-S256A nor AQP2-
S256D (not shown), which showed that in MDCK cells
(de-)phosphorylation of Ser-256 is not needed to exit the Golgi
complex.
In contrast to AQP2-S256A, AQP2-S256D was already ex-
pressed in the apical plasma membrane without stimulation of
the cAMP cascade with forskolin (Figs. 3 and 4). This revealed
that phosphorylation of just Ser-256 in AQP2 is sufficient for
AQP2 localization in the apical membrane and suggests that
other vasopressin-induced intracellular changes are not needed
for translocation of AQP2. This seems inconsistent with the
existing literature, because vasopressin-induced tethering of
PKA to AQP2-containing vesicles and depolymerization of the
actin cytoskeleton via inhibition of the Rho GTPase were
shown to be essential for AQP2 translocation to the plasma
membrane (39–41).
The following model might explain these possible contradic-
tions. AQP2 is thought to reside in two vesicle pools: a recycling
pool, which continuously shuttles AQP2 to and from the apical
membrane but rapidly changes the balance of AQP2 expression
to the apical membrane upon hormonal stimulation, and a
storage pool, which is transported along microtubules to the
apical pole and delivers its cargo to the recycling pool upon
stimulation (42–45). This hypothesis is consistent with the
biphasic increase in vasopressin-induced AQP2-mediated
water permeability in collecting ducts (46) and MDCK cells,2
because the latter process is much slower than the former. The
study presented here is consistent with this hypothesis of two
vesicle pools. The storage vesicles are detected as clear intra-
cellular spots, as observed for AQP2-S256A, and wt-AQP2 and
other AQP2 kinase mutants in unstimulated cells, whereas
AQP2 in the recycling pool is detected as being localized in the
apical membrane, as found for AQP2-S256D with or without
stimulation or for wt-AQP2 in stimulated cells. The assumption
that the latter protein cycles to and from the apical membrane
is corroborated by the data that treatment of stimulated wt-
AQP2 or AQP2-S256D cells with cytochalasin D, which affects
the actin cytoskeleton, resulted in numerous vesicles distrib-
uted throughout the cytoplasm (not shown). The constitutively
phosphorylated state of Ser-256, mimicked in AQP2-S256D,
thus conveys the protein a strong tendency to localize in recy-
cling vesicles instead of storage vesicles.
Of further interest is that apical cell surface biotinylation
experiments revealed that, although AQP1 and AQP2-Asn-220,
which is an AQP1 protein in which the C-tail is exchanged for
that of AQP2, are already expressed in the apical membrane of
MDCK cells without stimulation, forskolin still caused a nearly
2-fold increase in their apical membrane expression (47). In
contrast, the reporter protein TMR-Plap (47) and AQP2-S256D
(Fig. 4) did not show any increase in apical expression with
forskolin. These data suggest that, within the continuous shut-
tling process between recycling vesicles and the plasma mem-
brane, AQP2-S256D (and TMR-Plap) in unstimulated cells is
preferentially localized in the apical membrane, in contrast to
AQP1 and AQP2-Asn-220. Because the tendency of AQP2-
S256D to localize in the apical membrane is continuously pres-
ent, a slow uni-directional transport of AQP2-S256D from stor-
age vesicles to the apical membrane and/or a strongly reduced
endocytosis of AQP2-S256D from the plasma membrane follow-
ing the 3 days of culturing, provides an explanation for the
apical expression of AQP2-S256D in unstimulated cells, for
which PKA tethering and cytoskeletal rearrangements might
not be needed. Therefore, we believe that the apical membrane
localization of AQP2-S256D is not dependent on the transloca-
tion machinery needed to shuttle wt-AQP2 from storage vesi-
cles to the apical membrane but does reveal that, on a long
term, phosphorylation of AQP2 is sufficient for apical mem-
brane localization.
PMA-induced Endocytosis of AQP2 Occurs Independently of
the Phosphorylation State of AQP2—In terminal IMCD seg-
ments, activation of the PKC pathway has been shown to
counteract the AVP-induced AQP2-mediated water permeabil-
ity by increasing the vesicular versus apical membrane local-
ization of AQP2. In MDCK cells, this process could be mimicked
by PMA treatment, because, following forskolin stimulation,
this drug triggered the re-distribution of AQP2 proteins from
the apical membrane to intracellular vesicles.
Three different types of experiments provided information on
the role of phosphorylation of the putative AQP2 kinase sites in
the PMA-induced PKC-mediated endocytosis of AQP2. First,
wt-AQP2 and all kinase site mutants, with the exception of
AQP2-S256A/S256D mutants, were targeted to intracellular
vesicles without stimulation and were re-distributed to the
apical membrane upon forskolin treatment (Figs. 3 and 4). This
indicated that neither the constitutively phosphorylated state
of the putative PKC site, nor the constitutively (de-)phos-
phorylated state of any CKII site, was sufficient to maintain a
steady state vesicular localization upon treatment with forsko-
lin. Second, PMA treatment did not result in the phosphoryla-
tion of any putative phosphorylation site, as shown by the lack
of phosphate labeling of AQP2-S256A (Fig. 5). Third, PMA-
forskolin treatment following forskolin stimulation re-distrib-
uted all kinase site mutants from the apical membrane to vesi-
cles throughout the cell, which indicated the PMA-induced
endocytosis overruled the apical membrane targeting triggered
by Ser-256 phosphorylation. This was underscored by the finding
that all kinase site mutants were still phosphorylated at Ser-256
to a high extent although they were located in vesicles (Fig. 6).
Our data, therefore, strongly suggest that a PKC-induced
retrieval of AQP2 from the apical membrane of collecting duct
cells is a process that occurs independently of the phosphoryl-
ation state of AQP2. For Ser-256 in AQP2, this hypothesis is in
line with data from Zelenina et al. (35), who showed that in
isolated rat inner medulla prostaglandin E2 induces internal-
ization of AQP2 without decreasing the amount of PKA-phos-
phorylated AQP2. In collecting ducts, vasopressin is known to
induce a de- and re-polymerization of the actin cytoskeleton
(48), and cytochalasins, which disrupt actin filaments, mark-
edly inhibit the vasopressin response in target epithelia (49). In
addition, it has been shown that Rho, which belongs to a family
of proteins involved in the regulation of F-actin polymerization,
inhibits the translocation of AQP2 to the plasma membrane in2 P. M. T. Deen, unpublished data.
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cultured cells (40, 41). Because PKC activation has been shown
to disintegrate the actin cytoskeleton in confluent MDCK
monolayers (14, 50), it is therefore most likely that the inhib-
itory effect of PMA-activated PKC pathways on vasopressin-
induced AQP2 translocation to the apical membrane is con-
veyed through cytoskeletal rearrangements.
REFERENCES
1. Chou, C. L., Yip, K. P., Michea, L., Kador, K., Ferraris, J. D., Wade, J. B., and
Knepper, M. A. (2000) J. Biol. Chem. 275, 36839–36846
2. Deen, P. M. T., and Knoers, N. V. A. M. (1998) Curr. Opin. Nephrol. Hypertens.
7, 37–42
3. Nielsen, S., Frokiaer, J., and Knepper, M. A. (1998) Curr. Opin. Nephrol.
Hypertens. 7, 509–516
4. Nishimoto, G., Zelenina, M., Li, D., Yasui, M., Aperia, A., Nielsen, S., and
Nairn, A. C. (1999) Am. J. Physiol. 276, F254–F259
5. Christensen, B. M., Zelenina, M., Aperia, A., and Nielsen, S. (2000) Am. J.
Physiol. 278, F29–F42
6. Kamsteeg, E. J., Heijnen, I., van Os, C. H., and Deen, P. M. T. (2000) J. Cell
Biol. 151, 919–930
7. Katsura, T., Gustafson, C. E., Ausiello, D. A., and Brown, D. (1997) Am. J.
Physiol. 41, F816–F822
8. Fushimi, K., Sasaki, S., and Marumo, F. (1997) J. Biol. Chem. 272,
14800–14804
9. Kishore, B. K., Chou, C. L., and Knepper, M. A. (1995) Am. J. Physiol. 38,
F863–F869
10. Nadler, S. P., Zimpelmann, J. A., and Hebert, R. L. (1992) J. Clin. Invest. 90,
1458–1466
11. Nadler, S. P., Zimpelmann, J. A., and Hebert, R. L. (1992) Am. J. Physiol. 262,
F229–F235
12. Maeda, Y., Terada, Y., Nonoguchi, H., and Knepper, M. A. (1992) Am. J.
Physiol. 263, F319–F327
13. Han, J. S., Maeda, Y., Ecelbarger, C., and Knepper, M. A. (1994) Am. J.
Physiol. 266, F139–F146
14. Vaaraniemi, J., Palovuori, R., Lehto, V. P., and Eskelinen, S. (1999) J. Cell.
Physiol. 181, 83–95
15. Bren, G. D., Pennington, K. N., and Paya, C. V. (2000) J. Mol. Biol. 297,
1245–1258
16. Sanghera, J. S., Charlton, L. A., Paddon, H. B., and Pelech, S. L. (1992)
Biochem. J. 283, 829–837
17. Scott, D. B., Blanpied, T. A., Swanson, G. T., Zhang, C., and Ehlers, M. D.
(2001) J. Neurosci. 21, 3063–3072
18. Schlegel, A., Arvan, P., and Lisanti, M. P. (2001) J. Biol. Chem. 276,
4398–4408
19. Jones, B. G., Thomas, L., Molloy, S. S., Thulin, C. D., Fry, M. D., Walsh, K. A.,
and Thomas, G. (1995) EMBO J. 14, 5869–5883
20. van Tiel, C. M., Westerman, J., Paasman, M. A., Hoebens, M. M., Wirtz, K. W.,
and Snoek, G. T. (2002) J. Biol. Chem. 277, 22447–22452
21. Fujioka, T., and Ui, M. (2001) Eur. J. Biochem. 268, 25–34
22. Straussman, R., Even, L., and Ravid, S. (2001) J. Cell Sci. 114, 3047–3057
23. Maciejewski, P. M., Peterson, F. C., Anderson, P. J., and Brooks, C. L. (1995)
J. Biol. Chem. 270, 27661–27665
24. Egelhoff, T. T., Lee, R. J., and Spudich, J. A. (1993) Cell 75, 363–371
25. Estrera, V. T., Chen, D. T., Luo, W., Hixson, D. C., and Lin, S. H. (2001) J. Biol.
Chem. 276, 15547–15553
26. Zhang, W. Y., Gaynor, P. M., and Kruth, H. S. (1997) J. Biol. Chem. 272,
31700–31706
27. Deen, P. M. T., Rijss, J. P. L., Mulders, S. M., Errington, R. J., van Baal, J., and
van Os, C. H. (1997) J. Am. Soc. Nephrol. 8, 1493–1501
28. Mulders, S. M., Bichet, D. G., Rijss, J. P. L., Kamsteeg, E. J., Arthus, M. F.,
Lonergan, M., Fujiwara, M., Morgan, K., Leijendekker, R., van der Sluijs,
P., van Os, C. H., and Deen, P. M. T. (1998) J. Clin. Invest. 102, 57–66
29. Brewer, C. B. (1994) Methods Cell Biol. 43, 233–245
30. Graham, F. L., and Eb, A. J. (1973) Virology 52, 456–467
31. Deen, P. M. T., Nielsen, S., Bindels, R. J. M., and van Os, C. H. (1997) Pfluegers
Arch. 433, 780–787
32. Deen, P. M. T., Croes, H., van Aubel, R. A., Ginsel, L. A., and van Os, C. H.
(1995) J. Clin. Invest. 95, 2291–2296
33. Deen, P. M. T., van Aubel, R. A., van Lieburg, A. F., and van Os, C. H. (1996)
J. Am. Soc. Nephrol. 7, 836–841
34. Marr, N., Bichet, D. G., Lonergan, M., Arthus, M. F., Jeck, N., Seyberth, H. W.,
Rosenthal, W., van Os, C. H., Oksche, A., and Deen, P. M. (2002) Hum. Mol.
Genet. 11, 779–789
35. Zelenina, M., Christensen, B. M., Palmer, J., Nairn, A. C., Nielsen, S., and
Aperia, A. (2000) Am. J. Physiol. 278, F388–F394
36. Deen, P. M. T., and Brown, D. (2001) in Trafficking of Native and Mutant
Mammalian MIP Proteins (Hohmann, S., Agre, P., and Nielsen, S., eds), pp.
235–276, Academic Press, San Diego, CA
37. Berl, T. (1997) Kidney Int. S2–S5
38. Procino, G., Brunati, A. M., Marin, O., Contri, A., Pinna, L. A., Svelto, M., and
Valenti, G. (1999) J. Am. Soc. Nephrol. 10, 23
39. Klussmann, E., Maric, K., Wiesner, B., Beyermann, M., and Rosenthal, W.
(1999) J. Biol. Chem. 274, 4934–4938
40. Tamma, G., Klussmann, E., Maric, K., Aktories, K., Svelto, M., Rosenthal, W.,
and Valenti, G. (2001) Am. J. Physiol. 281, F1092–F1101
41. Klussmann, E., Tamma, G., Lorenz, D., Wiesner, B., Maric, K., Hofmann, F.,
Aktories, K., Valenti, G., and Rosenthal, W. (2001) J. Biol. Chem. 276,
20451–20457
42. Phillips, M. E., and Taylor, A. (1992) J. Physiol. (Lond.) 456, 591–608
43. Phillips, M. E., and Taylor, A. (1989) J. Physiol. (Lond.) 411, 529–544
44. Breton, S., and Brown, D. (1998) J. Am. Soc. Nephrol. 9, 155–166
45. Klussmann, E., Maric, K., and Rosenthal, W. (2000) Rev. Physiol. Biochem.
Pharmacol. 141, 33–95
46. Wall, S. M., Han, J. S., Chou, C. L., and Knepper, M. A. (1992) Am. J. Physiol.
262, F989–F998
47. Deen, P. M. T., van Balkom, B. W., Savelkoul, P. J., Kamsteeg, E. J., Van Raak,
M., Jennings, M. L., Muth, T. R., Rajendran, V., and Caplan, M. J. (2002)
Am. J. Physiol. 282, F330–F340
48. Simon, H., Gao, Y., Franki, N., and Hays, R. M. (1993) Am. J. Physiol. 265,
C757–C762
49. Pearl, M., and Taylor, A. (1985) Biol. Cell 55, 163–172
50. Keenan, C., and Kelleher, D. (1998) Cell. Signal. 10, 225–232
Phosphorylation of AQP2 41479
 at UQ Library on October 16, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Nielsen, Peter van der Sluijs and Peter M. T. Deen
Bas W. M. van Balkom, Paul J. M. Savelkoul, Daniel Markovich, Erik Hofman, Soren
Aquaporin-2 Water Channel
The Role of Putative Phosphorylation Sites in the Targeting and Shuttling of the
doi: 10.1074/jbc.M207525200 originally published online August 22, 2002
2002, 277:41473-41479.J. Biol. Chem. 
  
 10.1074/jbc.M207525200Access the most updated version of this article at doi: 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
  
 http://www.jbc.org/content/277/44/41473.full.html#ref-list-1
This article cites 48 references, 16 of which can be accessed free at
 at UQ Library on October 16, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
